Based on the clinical outcome, ERα-negative P53(+) patients showed a better chemoresponse (necrosis rate > 90%, Table 1), indicating that ERα may be a potential target for treatments with combinations of current chemoadjuvants to improve the chemosensitivity of osteosarcoma therapy. This evidence concerns the gene ESR1 and osteosarcoma.